Xiang-Yuan Liu
Overview
Explore the profile of Xiang-Yuan Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
269
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li C, Ma Z, Jian L, Wang X, Sun L, Liu X, et al.
Int Immunopharmacol
. 2020 Dec;
90:107219.
PMID: 33307512
Background: Iguratimod, a small molecular drug, has been proven to have effective bone protection for treatment of patients with bone loss-related diseases, such as rheumatoid arthritis (RA). However, the exact...
2.
Li X, Duan H, Liu X, Deng X
Chin Med J (Engl)
. 2020 Aug;
133(19):2287-2294.
PMID: 32842014
Background: B-cell activating factor (BAFF) is vital for B cell survival. Serum BAFF levels are elevated in thrombotic antiphospholipid syndrome, but little is known about levels in patients with positive...
3.
Li C, Xu L, Jian L, Yu R, Zhao J, Sun L, et al.
Int Immunopharmacol
. 2018 Mar;
58:136-144.
PMID: 29587202
Tofacitinib, a small molecule JAK inhibitor, has been widely used to reduce inflammation and inhibit progression of bone destruction in rheumatoid arthritis. STAT3, a downstream signaling molecule of JAK, plays...
4.
Liu A, Yang Y, Li M, Jia Y, Chen S, Ye S, et al.
Clin Rheumatol
. 2017 Apr;
37(1):93-100.
PMID: 28409239
The objective of this study was to describe the clinical and laboratory characteristics, precipitating factors, treatment, and outcome of macrophage activation syndrome (MAS) complicating systemic lupus erythematosus (SLE). A multicenter...
5.
He J, Wang Y, Feng M, Zhang X, Jin Y, Li X, et al.
Clin Rheumatol
. 2016 Aug;
35(12):2901-2908.
PMID: 27553386
Environmental factors play an important role in the development of rheumatoid arthritis (RA). Among these factors, smoking is generally considered to be an established risk factor for RA. Data regarding...
6.
Li R, Zhao J, Su Y, He J, Chen L, Gu F, et al.
Medicine (Baltimore)
. 2016 Jul;
95(28):e3968.
PMID: 27428186
Objectives: To determine whether prolonged intensive disease-modifying antirheumatic drug (DMARD) treatment (PRINT) leads to high remission and low relapse rates in patients with severe rheumatoid arthritis (RA). Methods: In this...
7.
Li R, Liu X, Ye H, Yao H, Guo J, Li G, et al.
Clin Rheumatol
. 2016 Jan;
35(2):303-8.
PMID: 26781784
To identify the magnetic resonance imaging (MRI) features of hands and wrists in early rheumatoid arthritis (RA). A total of 129 early arthritis patients (≤1 year) were enrolled in the...
8.
Li C, Xu L, Zhao J, Sun L, Yao Z, Deng X, et al.
Inflamm Res
. 2015 Dec;
65(3):193-202.
PMID: 26621504
Objective: To explore the influence of chemokine, CXCL16, on the expression of the receptor activator nuclear factor κB ligand (RANKL) in rheumatoid arthritis (RA) fibroblast-like synoviocytes (RA-FLS). Methods: The expression...
9.
Ren L, Li R, Chen L, Zhu P, Gu F, Sun L, et al.
Int J Rheum Dis
. 2015 Aug;
19(7):651-7.
PMID: 26268935
Aim: The aim of this study was to determine the efficacy and safety of a weekly dose of leflunomide (50 mg/week) in early rheumatoid arthritis patients with mild or moderate...
10.
Wang G, Zhang S, Wang X, Feng M, Li C, An Y, et al.
Clin Rheumatol
. 2014 Nov;
34(2):221-30.
PMID: 25413735
The aim of this study is to investigate the remission rate of rheumatoid arthritis (RA) in China and identify its potential determinants. A multi-center cross-sectional study was conducted from July...